HRS 9815
Alternative Names: HRS-9815; HRS-9815 Injection Preparation KitLatest Information Update: 28 Nov 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Emission-computed tomography enhancers; Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 28 Nov 2023 Phase-I clinical trials in Prostate cancer (Diagnosis) (Parenteral), prior to November 2023 (Jiangsu HengRui Medicine pipeline, November 2023)
- 03 Oct 2023 Jiangsu HengRui Medicine plans a phase I trial in Prostate cancer (Diagnosis) in China (Injection) in October 2023 (NCT06062355)
- 10 Jul 2023 NMPA approves IND application for HRS 9815 in Prostate cancer